Introduction
genetic and epigenetic alterations.
In the recent years, much of the research in breast cancer has been focused in the characterization and functional analysis of epigenetic alterations (Feinberg et al., 2004; Esteller 2008; Parrella 2010 , Baylin et al., 2011 . The main epigenetic alterations consist in DNA methylation, histone modifications such as acetylation, methylation and phosphorylation, and translational interference by micro-RNAs.
Aberrant DNA methylation plays a pivotal role in the development of different types of cancer. DNA methylation occurs mainly in cytosines preceding guanines and together they are known as CpG dinucleotides; they are found at high density in the promoter sites in most of the genes, which are named CpG islands. In this way, promoter methylation of genes represents a key event in cancer development because it is translated in gene silencing; so, the study of methylated genes represents the emergence of epigenetic biomarkers (Esteller 2008; Baylin et al., 2011; Heichman et al., 2012) .
On the other hand, the role played by ER and PR in the breast cancer development is well known (Radisky et al., 2007; Allred 2010; Castoria et al., 2010) ; estrogens drive the cancer development and tumors expressing ER are more differentiated and responsive to treatments based on anti estrogens (i.e. tamoxifen) or aromatase inhibitors (i.e. anastrozole) (Renoir et al., 2013) . Likewise, PR also provide useful information in defining subgroups of responders to therapy (Allred et al., 2010; Knutson et al., 2013; Purdie et al., 2014) .
Estrogen receptor-α (ER-α) is encoded by the ESR1 gene, located in chromosome 6; its transcription is under control of seven promoters, two of them, named A and B contain CpG islands. In breast cancer, the estrogenic signaling pathway is involved in diverse grade. The immunohistochemical determination of ER-α is the conventional method and the gold standard, although it is accepted that there are unsolved questions regarding heterogeneity in staining methods and arbitrary criteria for interpreting the results, which can result in specificity with up to 20% of false negatives (Allred 2010; Hammond et al., 2010) . The PR is encoded in the PGR gene located in chromosome 11, under control by two promoters, named A and B, which as A and B ESR1 promoters, contain CpG islands. Immunohistochemical determination of PR involves the same problems of staining and interpretation depicted above for ER-α (Allred 2010; Hammond et al., 2010) .
The determination of ESR1 and PGR promoter methylation has scantly been studied (Lapidus et al., 1998; Mc Cormack et al., 2007; Gaudet et al., 2009; Ramezani et al., 2012) , with results not definitive to date. Methylation analysis could represent an early biomarker and also an alternative or complement to the ER and PR immunohistochemical determination in breast cancer, with potential for be determined in circulating DNA (Sturgeon et al., 2012) , which could be of help with diverse purposes in clinical stages.
The aim of this work was to analyze the methylation status of promoters containing CpG islands in the ESR1 and PGR genes, and to determine their correlation with the immunohistochemical determination of ER and PR in ductal and lobular breast cancer.
Materials and Methods
A correlational, observational, descriptive molecular study was conducted in excisional biopsies obtained with therapeutic aim from women resident of the north of Mexico. Twenty ductal (18 infiltrating, and 2 in situ) and 20 lobular infiltrating breast cancer cases, with immunohistochemical determination of ER and PR qualitatively determined as positive or negative, were studied. Written informed consent was obtained.
DNA extraction
DNA was purified from a 100-300 mg tissue sample by homogenization with 1 ml of DNAzol solution (Invitrogen, Carlsbad, CA), followed by centrifugation at 10,000xg by 5 min; the supernatant was mixed with 0.5 mL absolute ethanol and the precipitated DNA was collected by brief centrifugation, washed twice with 70% ethanol and finally resuspended in water. The DNA quantification was done by absorbance at 260nm and integrity assessed by agarose gel electrophoresis and ethidium bromide staining.
Bisulfite modification and methylation analysis
Qualitative analysis of the ESR1 and PGR promoters was done by methylation specific PCR (MSP) (Herman et al., 2001) , which employs bisulfate-modified DNA; 1 µg of DNA was modified with the IMPRINT DNA Modification Kit (MOD50, Sigma Aldrich, St. Louis, MO) according to the manufacturer's protocol. The modified DNA was stored at -36˚C until its analysis within the next 20 days. For MSP analysis, primers for CpG islands in ESR1 and PGR were selected according to previous reports (Lapidus et al., 1998; Sasaki et al., 2001) . MSP was performed using 1μl of the modified DNA in a final reaction volume of 25μl, containing 12.5μl of GoTaq Master Mix (Promega Inc., Madison, WI, USA), 0.5μl of each forward and reverse primers for unmethylated (UM) and methylated (M) promoters (Table 1) , and 10.5μl of water. Primers were synthesized by Integrated DNA Technologies (Coralville, IA). The PCR amplification consisted of 35 cycles of denaturation at 95˚C for 45 sec, annealing at 55˚C for 45 sec and extension at 72˚C for 45 sec. The amplification products were analyzed by agarose gel electrophoresis with ethidium bromide staining.
Statistical analysis
Descriptive statistics and Kendall's tau correlation coefficient were analyzed with the on-line Free Statistics Software (Wessa, 2011) .
Results

Age group
The median age of the entire sample was 54 years, with an inter-quartile range between 47 and 60.75 years; in the ductal carcinoma group, the median age was 53 years with an inter-quartile range between 47 and 66 years; in the lobular carcinoma group, the median age was 54.5 years with an inter-quartile range between 48 and 60 years.
E s t ro g e n a n d p ro g e s t e ro n e re c e p t o r s b y immunohistochemistry
The proportion of positivity for ER and PR in the sample was 0.72 and 0.80 respectively, with a variable degree of positivity going from 10 to 100% (not shown). The frequency of ER and PR by histological type is shown in Table 2 . Figure 1 .
Methylation of ESR1 and PGR promoters
ESR1 and PGR Gene Promoter Methylation and Estrogen and Progesterone Receptors in Breast Cancer For ESR1, the promoter was found mainly unmethylated in a proportion of 0.85. For PGR, the promoter was found as for ESR1
Figure 2. Lobular Breast Cancer. Correlation matrix of estrogen receptors (ER), progesterone receptors (PR), unmethylated ESR1 promoter (UM-ESR1), methylated ESR1 promoter (M-ESR1), methylated PGR promoter (M-PGR). For every plot in the diagonally upper half, there is a corresponding p value in the lower half and PR, ER and UM-PGR, PR and UM-PGR. A negative correlation was observed between: ER and M-PGR, PR and M-PGR, UM-ESR1 and M-ESR1, UM-PGR and M-PGR. Correlation matrix is shown in
Correlation of promoter methylation status of ESR1 and PGR with the presence of ER and PR in lobular breast carcinoma
A positive correlation was observed between: ER and PR. A negative correlation was observed between: PR and M-PGR promoter. UM-PGR was not included in the analysis because the sample showed homogeneity. Correlation matrix is shown in Figure 2 .
Discussion
Breast cancer is a heterogeneous and plastic disease with many subjacent genetic and epigenetic abnormalities. Additionally to the information supplied by the histopathological diagnosis of breast cancer, the molecular classification offers information of importance for evaluating multiple aspects as the groups differ in evolution, survival and response to treatment, by which is essential to determine the molecular type; this classification is based in the expression of ER, PR and HER2, including four molecular sub-groups: luminal A and B, HER2 over-expression and basal-like.
In spite of these achievements, there exists a consensus On the other hand, negative correlations were found between the M-PGR promoter, ER and PR, which also is the expected because the promoter methylation means gene silencing, although this correlation was not observed with the ESR1 promoter. Other negative correlations observed were between M-ESR1 and UM-ESR1 promoter, as well as between the M-PGR and UM-PGR, which is biologically plausible and confirms the trend of the promoters towards any or other methylation status. In the lobular breast cancer type, a negative correlation was observed between PR and the UM-PGR promoter; in this histological type, there were few cases of non methylated promoter which impeded the study of some correlations. It is of note that M-ESR1 and M-PGR promoters in both ductal and lobular cancer samples, were discordant in some individual samples, which merits further study.
In conclusion, the results here shown suggest that the methylation of ESR1 and PGR promoters is an infrequent event in the most frequent histological types of breast cancer; they also suggest that the methylation analysis of the ESR1 and PGR promoters could represent an alternative or complement to the immunochemical expression analysis, although further studies are needed.
The DNA methylation analysis is highly sensible and specific, which is appealing for the development of methylation-based biomarkers; however, studies regarding quantitative methylation analysis, pyrosequencing, determination in serum DNA and many other issues are needed before they can be useful with diverse aim in breast cancer.
